文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

秘鲁医护人员接种BBIBP-CorV新冠疫苗的上市后安全性监测

Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
PubMed 文献 · Vaccine · 2026-01-17

该研究基于秘鲁EsSalud药物警戒中心数据,回顾性分析2021年2月至8月医护人员接种BBIBP-CorV后的AEFI报告。

要点

  • AEFI报告率为1052/10万剂(95%CI 1009-1097),以轻症为主。
  • 女性胃肠道事件更多,男性一般性疾病更多,≥65岁血管和眼部事件更多。

核心结论

  • BBIBP-CorV在秘鲁医护人员中AEFI报告率低,事件多为轻度。

研究设计与样本

  • 回顾性分析秘鲁EsSalud药物警戒中心2021年2月至8月医护人员接种BBIBP-CorV后的AEFI报告。

主要发现

  • 共识别2280份AEFI报告,对应4376个不良事件术语。
  • 22例符合AESI标准,仅2例过敏反应与疫苗存在因果关联(A1)。
  • 4354个事件归入14个MedDRA SOC分类,神经系统紊乱占30%、注射部位反应占11%最常见。
  • 女性胃肠道事件发生率12.6% vs 男性7.9%(p<0.001),男性一般性疾病16% vs 女性10.9%(p<0.001)。

临床怎么用

  • 接种BBIBP-CorV后应关注过敏反应等AESI,并依托医疗记录开展因果评估。
  • 药物警戒数据可用于支持本地公共卫生决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The inactivated SARS-CoV-2 vaccine (BBIBP-CorV) was first introduced in Peru among healthcare workers. We evaluated its safety profile by analyzing adverse events following immunization (AEFI) reports and conducting clinical and causality assessments for cases meeting criteria for adverse events of special interest (AESI) and serious adverse events (SAEs). METHODS: We conducted a retrospective analysis using data from the Pharmacovigilance Center of EsSalud. We identified, estimated the overall reporting rate, and described key characteristics of AEFI reports, including differences by gender and age group. Clinicians trained in vaccine safety performed clinical assessments for AESIs and SAEs based on medical records and conducted formal causality assessments. RESULTS: From February to August 2021, we identified 2280 AEFI reports (1052 per 100,000 doses; 95% CI 1009-1097), corresponding to 4376 adverse event terms. Of these, 22 met AESI criteria, with only two anaphylaxis cases causally linked to the vaccine (A1). The remaining 4354 events were grouped into 14 MedDRA SOC categories, with nervous system disorders (30%) and injection site reactions (11%) most frequent. Gastrointestinal events were more common in women (12.6% vs. 7.9%, p < 0.001), while men reported more general disorders (16% vs. 10.9%, p < 0.001). Adults ≥65 years reported more vascular and eye disorders. Fifteen events were categorized as SAEs and classified as category C. CONCLUSIONS: This first post-marketing safety evaluation of BBIBP-CorV among Peruvian healthcare personnel found a low AEFI reporting rate, with mostly mild events. Access to medical records enabled accurate assessment, supporting local pharmacovigilance and public health decision-making.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yesenia Rodríguez-Tanta L, Delgado-Escalante R, Del Pilar Solis-Yucra T, et al. Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center. Vaccine. 2026. PMID: 41548527. doi:10.1016/j.vaccine.2026.128227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。